Voyager doses first patient with anti-tau antibody in Alzheimer’s trial

Voyager Therapeutics has dosed the first patient in a Phase Ia single-ascending dose study of its investigational anti-tau antibody VY-TAU01 for patients with Alzheimer’s disease.

The trial will be a randomised, double-blind, placebo-controlled study evaluating the safety and pharmacokinetics of VY-TAU01 in 48 healthy adults. Patients will be randomised to receive intravenously delivered candidate or a placebo. The company plans to initiate a Phase Ib multiple-ascending dose study in 2025, following data from the Phase Ia trial.